Many US multiple sclerosis (MS) patients aren’t receiving the latest drug therapies, according to research published in the online journal BMC Medicine.
Immunomodulatory agents (IMAs) could slow the progress of the disease, but are only prescribed in a minority of cases, and mostly by neurologists.
Jagannadha Avasarala from Kansas Neurological Consultants, Wichita analysed treatment trends between 1998 and 2004 for all Federal Drug Administration (FDA) approved IMA drugs, together with colleagues from Wake Forest University School of Medicine, NC, and Ohio State University Medical Center. They used National Ambulatory Medical Care Survey (NAMCS) data to evaluate prescribing trends as well as type of physician and geographic location.
Avasarala found that an estimated 6.7million MS patient visits occurred during the study timescale: 3.4 visits per 1000 persons each year. Women were seen four times as often as men and Caucasians had a higher visit rate than African Americans (90% vs 8%). This may because MS is more prevalent amongst Caucasian women than any one ethnic group. Neurologists prescribed IMAs more often than family practitioners or internists, with urban patients visited neurologists than their rural counterparts. The NAMCS data showed that 62% of established MS patients evaluated by neurologists and 92% of those seeing family medicine practitioners or internists were not being treated with IMAs. The higher treatment rate among neurologists probably reflects greater awareness of these drugs and familiarity with MS cases.
“Strategies for educating both neurologists and non-neurologists about the benefits of initiating IMA use in MS patients and in continuing their use remain critical to improving long-term patient outcomes in treatment of MS” Says Avasarala.
MS is among the leading causes of disability in young adults, and accumulates over time. IMAs can reduce the frequency of new lesions, relapses and the rate of cerebral atrophy.
Source: Biomed Central
Filed under Health, Multiple Sclerosis
Related?
Multiple Sclerosis Sufferer Could Move Again After stem-Cell TreatmentJune 10th, 2006 Presently stem-cell treatment is banned in Britain, but a multiple sclerosis sufferer who went abroad for stem-cell treatment, can now move his hands and feet for the first time in years.
Rob Hodgson, from Elloughton near Hull, has been forced to use a wheelchair for the last 18 months and was unable to move the [...]
Novartis says FDA approved Extavia in relapsing-remitting MS and first episodes of diseaseAugust 17th, 2009 Novartis says FDA approves interferon drug for MSNEW YORK — Novartis AG said Monday the U.S. Food and Drug Administration approved its drug Extavia, a form of interferon intended to treat multiple sclerosis.
Cure for multiple sclerosis now possibleAugust 13th, 2009 TORONTO - Canadian researchers have successfully reversed multiple sclerosis in rodents, spelling hope for humans. Multiple sclerosis is an auto-immune disease in which the body's own immune response attacks the central nervous system, leading to progressive physical and mental deterioration.
Boffins successfully reverse multiple sclerosis in miceAugust 12th, 2009 LONDON - In a breakthrough study, researchers have successfully reversed multiple sclerosis in mice with the help of a new experimental treatment. According to researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal, the new treatment known as GIFT15 has reversed the devastating autoimmune disorder in mice, and might work exactly the same way in humans.
Free From Mutiple Sclerosis Pain After 12 Years; Thanks to Pioneering Stem Cell ResearchMay 1st, 2006 A Scottish man (Mark Westwell, 45), with multiple sclerosis (MS) claims to be pain-free for the first time in 12 years after a controversial stem-cell procedure in a Co Cork clinic, which is at the centre of an investigation. Mark received the treatment pioneered by a Swiss biotechnology company, Advanced Cell Therapeutics, earlier this month.
Cheap BP drug could help treat multiple sclerosisAugust 18th, 2009 WASHINGTON - A cheap blood pressure drug could help keep multiple sclerosis at bay, claim researchers at the Stanford University School of Medicine. The study's boffins came to the conclusion after finding a link, in mice and in human brain tissue, between high blood pressure and multiple sclerosis.
New pill to replace painful multiple sclerosis jabsApril 30th, 2009 WASHINGTON - A new pill may soon replace the painful injections for multiple sclerosis treatment, say researchers. The research team led by Professor Gavin Giovannoni of Barts and The London School of Medicine and Dentistry has shown that cladribine tablets just a few times a year can reduce the chances of a relapse by well over 50 per cent.
Two experimental drug hold hope for multiple sclerosis treatmentOctober 27th, 2008 Patients of multiple sclerosis may find ray of hope in two experimental drug. One is called oral fumarate (BG00012) substantially reduced symptoms in patients with relapsing-remitting multiple sclerosis, in the phase II clinical trial.
